BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing the First Personalized OTC Immunotherapy Drug for Advanced Breast Cancer
41,000 women in the U.S. are expected to die of breast cancer in 2018 BriaCell is developing a breast cancer drug that can be quickly prepared for individualized treatment Clinical trials demonstrate tumor shrinkage with no serious side effects BriaCell is now in clinical trials with its lead immunotherapy treatment, tested in combination with other already-approved cancer fighting drugs Immunotherapy drugs are expected to be a $100 billion business by 2021 Breast cancer is the second-leading cause of cancer death for U.S. women. Although death rates from this disease have been falling since 1989, still in 2018 nearly 41,000 Americans…